|
|
Post by goldencoin9999 on Nov 20, 2015 0:17:29 GMT
Just wondering if anyone will be joining the law suit from SCOTT NADLE?
|
|
|
|
Post by vzveteran on Nov 20, 2015 1:53:25 GMT
Why not join in? You can withdraw at any time, and the company has the opportunity to raise the offer to plaintiff's satisfaction. At which point the suit will be dropped.
|
|
|
|
Post by goldencoin9999 on Nov 20, 2015 2:26:14 GMT
I don't have experience with class action law suit. How would you go about joining?
|
|
|
|
Post by vzveteran on Nov 20, 2015 2:48:51 GMT
|
|
|
|
Post by goldencoin9999 on Nov 20, 2015 2:53:12 GMT
Thanks, vzveteran!
|
|
|
|
Post by invest on Nov 20, 2015 3:00:42 GMT
I believe, If they win you win....as long as you owned shares during 'X' period
|
|
|
|
Post by spambox on Nov 20, 2015 3:21:25 GMT
Yeah it usually reflects to all holders as of a specific date. I'm sitting on the 'wait and see' fence.
|
|
|
|
Post by rickrick on Nov 21, 2015 6:57:10 GMT
This is a done deal, it's over, big pharma has won.
There is no way any lawsuit will win, don't fall prey to the lawyers as we did for this stock. We have been taken advantage of since the very beginning and as far as any court will be concerned we are accountable for all of our actions.
The new management has done nothing wrong in the eyes of the law, they didn't lie, they didn't over promise, they just did what penny stock companies do and that's rely on the hopes and dreams of the get rich quick mentality that we are all guilty of since the beginning.
Jason and CDC did the same thing, will there be a lawsuit against them?
I respect all those I know that from the very beginning recognized what this company was and stayed away refusing to invest while the majority of us was shouting how this was going to save the world and the blind.
Big pharma and the government still and always will control the industry, it's the nature of the beast.
Whatever the Japanese have planned for the science will still be exploited and used for the wealthy to make money, that's the way this world is.
|
|
razor
New Member
Posts: 22 
|
Post by razor on Nov 21, 2015 13:37:42 GMT
This is a done deal, it's over, big pharma has won. There is no way any lawsuit will win, don't fall prey to the lawyers as we did for this stock. We have been taken advantage of since the very beginning and as far as any court will be concerned we are accountable for all of our actions. The new management has done nothing wrong in the eyes of the law, they didn't lie, they didn't over promise, they just did what penny stock companies do and that's rely on the hopes and dreams of the get rich quick mentality that we are all guilty of since the beginning. Jason and CDC did the same thing, will there be a lawsuit against them? I respect all those I know that from the very beginning recognized what this company was and stayed away refusing to invest while the majority of us was shouting how this was going to save the world and the blind. Big pharma and the government still and always will control the industry, it's the nature of the beast. Whatever the Japanese have planned for the science will still be exploited and used for the wealthy to make money, that's the way this world is. |
|
razor
New Member
Posts: 22
|
Post by razor on Nov 21, 2015 13:47:18 GMT
Agree. IMO CDC and others will have the lemmings chasing the Astellas bus as it pulls away when the deal is final. I've sold my OCAT and I've taken a position in ASTELLAS (ALPMY)for the small bump when it comes. Sell order is in at @ 19.  |
|
|
|
Post by nateb on Nov 21, 2015 14:44:37 GMT
Agreed. This is done... time to move on. For everyone else, don't waste your time with the lawyers. If they win, and that is a big IF, they make the cash,while you get the spare change. There are plenty of other multi-bagger potential opportunities out there *****************. I sold my shares and it was like breaking up with a long term girlfriend. Sad but at the same time liberating.
*EDIT* - nateb i went ahead and edited out the stocks you mentioned as potential mutli-baggers. Even though I know you didn't mean anything by it, it's a good idea not to "promote" other stocks on the OCAT board. Thanks!
JHam
|
|
|
|
Post by harlem on Nov 21, 2015 15:22:51 GMT
The deal is done. Joining the lawsuit just involves sending in a statement from your account showing your shares and losses if you have any. The lawyers will send out forms to fill out. IF (this is a BIG IF) the lawsuit gets won or settled, the funds will first feed the lawyers and then are distributed to the investors. In the Citigroup lawsuit, after the lawyers were done with the $880 million settlement -- investors received three cents on the dollar for their documented losses. Given the appetite of the lawyers, an award or settlement of millions or even tens of millions (unlikely) would have investors being lucky to get back the cost of postage to mail the forms. all imho with some experience glta
|
|
|
|
Post by JHam on Nov 21, 2015 16:21:10 GMT
Agreed. This is done... time to move on. For everyone else, don't waste your time with the lawyers. If they win, and that is a big IF, they make the cash,while you get the spare change. There are plenty of other multi-bagger potential opportunities out there *****************. I sold my shares and it was like breaking up with a long term girlfriend. Sad but at the same time liberating. *EDIT* - nateb i went ahead and edited out the stocks you mentioned as potential mutli-baggers. Even though I know you didn't mean anything by it, it's a good idea not to "promote" other stocks on the OCAT board. Thanks!
JHam nateb, check out the edit when you have a chance. Thanks! JHam |
|
|
|
Post by invest on Nov 21, 2015 16:48:56 GMT
Why wouldn't you not join? There will be no cost to you and you literally don't have to do much if anything at all. As a large shareholder I am in, any return will be a plus.
Keep in mind it's a class action which represents all shareholders.
To quickly add I am not tendering my shares. I'll wait for the bid to increase.
|
|
|
|
Post by actcforme on Nov 21, 2015 18:51:12 GMT
There is no way we want to tie up our money on a lawsuit.
I personally am thrilled to have Gary Aronson in our corner, BUT I don't have the deep pockets that he does to tie up this much money.
I hold out hope Astellas comes back with better offer if only to avoid long, drawn out legal action (with Aronson involved that's what they'll get).
It is so disgusting to read old statements by Wotton and Ted and even Gary Rabin (who did NOT lie about the science IMO), about how BIG this will be, and then to literally give it away. Here are the samples I found comparing to REGN in chronological order. I believe it would be so easy to prove their lack of fiduciary responsibility to us, so much about the data we as shareholders have never even been told -- but Astellas is told (what's wrong with this picture). We only know about 18 of 44 patients. We only know leaks by Schwartz that two better vision patients from what he saw "looks good." We only know leaks about Tufts dogs by Dr. Hoffman and that looks great.
I will never understand Paul NOT wanting to increase the share value and make public so much more of the good news of the pipeline.
I tend to agree, it is a perfect example of why people are so disillusioned with government and Wall Street, corruption and greed that has grown exponentially in this country.
Hope to escape with a modest profit with avg. of $7.20/share. Part of me wishes I sold at $8.65 this week.
1/28/13 BigCat Interview of Gary Rabin
Gary Rabin: We do not want to give up the "Golden Goose" in January of 2013 when we are so close to having Phase I done and starting Phase II. I have been clear that we do not want to partner the RPE program too early. We just cannot leave that much value on the table when you are going after markets this big. A small percentage of the market share of these massive degenerative diseases, with reasonable reimbursement rates, calculates into enormous revenue figures. With this program we have to make sure that people understand the efficacy. We need to advance the ball through Phase I and start Phase II. This is when you see these big changes in valuations from the pharmaceutical companies.
It's interesting that you mention those two companies (CUR/STEM). Spinal cord injury is a horrible disease/condition, and it would be wonderful if someone could go after that.
The truth is that there are about ten cell therapy products on the market right now. The cell therapy market is becoming a real industry; there is no question about that. When you talk to the big pharmaceutical companies, they all recognize the opportunity in cell therapy versus vaccines and molecules. There is just no question that this is an industry that is going to be big. We feel that we have the best opportunities and the biggest markets, when compared to the companies that you mentioned above. We also have the best business model and cost infrastructure with our off-the-shelf product. Another advantage is the scalability of our therapy. We can provide this with prices that are reasonable to both the company and the final end user. With all this going for us, these other programs just don't compare.
I'm not saying that these are not good programs. I think what Neuralstem, for example, has done is wonderful, and I wish them the best. ACT is just thinking on a much bigger scale.
4/14/13 Big Cat Article
Here is a quote from Mr. Rabin's Seeking Alpha interview that gives readers an indication as to what is going on behind the scenes:
"It is safe to say that if you talk to any biotech/pharma company that has an interest in ophthalmology, you will not find one of them that do not know every detail about our trials. In fact, we are at the point that we are almost pushing back, saying that we are not ready to give out the amount of due diligence material that they are asking for".
ACTC has stated that they are not going to give up the "Golden Goose" by partnering this stem cell therapy too early. They are not going to just give it away to get a joint venture for the sake of having one. If successful in the trials, there is big money to be made and the large pharmaceutical companies know this. With ACTC's well-established technological patents and an unmet medical need worth tens of billions, these large pharmaceutical companies should go to war with each other to see who controls this new frontier of medicine.
8/07/13 Conference Call
Gary Rabin: At the inflection point of value creation from the transition from Phase I to Phase II, and then from Phase II to Phase III, and then from Phase III to commercialization are ENORMOUS INFLECTIONS one can value, logarithmic jumps, and I have made it clear on every conference call, that we are not going to enter into a joint venture with what looks like the golden goose just to get 10 million dollars in the door. This is a potential multi-billion dollar therapy.
We've seen too much promise in this therapy to just partner it out for a small upfront payment. It would be crazy. So, I recognize what that means for shareholders is that you could be holding the stock for a while before we announce a partnership agreement, BUT THERE ARE PLENTY OF VALUE-CREATING INFLECTION POINTS BETWEEN NOW AND THEN, so that's what we're focused on.
4/25/14 Third Stem Cell Partnering Conference
Ted Myles: We're really building up to now that we're deep in the Phase I with a real look at Phase II, we are building our clinical organization, really shifting the emphasis of the company from research, purely research, to development and still funding what we refer to as sort of the Golden Goose that's creating a lot of great technology in the research programs but really focusing and shifting and allocating resources so that we can execute and succeed in the clinic.
A really rich pipeline of clinical and pre-clinical assets. Additionally, it's given us a chance to create a very leading, what we believe to be in a really valuable IP position. We don't think this has been fully unlocked yet, but we intend to do that in the near future.
5/11/14 iCell post by StemacularD
6. The Regeneron / Avalanche deal: $600 million for a stake in a mid-phase II Wet AMD Gene Therapy company. Schwartz' company. Our lead surgeon. This is another INCREDIBLE turn of events and should have investors rushing to their Etrade accounts to pick up a position in this company.
(a) It is not logical to assume Regeneron doesn't know all about that other project that Schwartz is working on. You know, that phase 1 RPE program with ACT.
(b) That Regeneron was willing to slap down $600 million for "fringe science" is a giant endorsement for all "fringe science" including Stem Cell Therapy. It means, flat out, that we are entering a new era. Old meets new.
(c) That Regeneron took such a bold move will necessarily force other pharmas to consider also making bold moves. Both from a defensive strategy (Regeneron now has a back up plan) to an aggressive strategy (think Pfizer with its aging pipeline). Now, I'm not suggesting we are getting bought out tomorrow (or that Pfizer is interested), but I am saying that Matt's words "we are at a tipping point" certainly hold alot more weight today than when he uttered them a couple weeks ago.
11/10/14 Conference Call
Paul Wotton: In contrast to dry AMD, wet AMD has a number of treatments available such as Lucentis, which is co-marketed by Novartis and Roche with global sales in excess of $3 billion dollars, or Eyelea, a product that was approved in late 2011, and marketed by Regeneron with sales of about $1.7 billion within three years of launch. I believe that our products in dry AMD is of a similar size based on confirmatory market research that we have just completed.
12/02/14: Piper Jaffray Investor Conference
Paul Wotton: Dry AMD is a precursor to wet AMD and most people well know, wet AMD is a blockbuster drug category itself. Lucentis by Roche Novartis and Eyelea by Regeneron are very successful therapies in that area. Obviously we would aspire to become a Regeneron type company in the future.
12/03-11/2014 Piper Jaffray Road Show
Paul Wotton: So we're developing products with potentially big markets. Now I'd like to think that at some point in the future this company could be like Regeneron. I certainly preach that in terms of market cap, but right now we're at $230 million dollar market cap, looking to raise financing in order to be able to progress these programs.
3/12/15 Conference Call
Paul Wotton: Our focus on the ophthalmology space also continues to be supported by market dynamics as well. Our own market research has confirmed that our therapies, if approved, could treat substantial numbers of patients with dry AMD and Stargardt's disease where no meaningful therapy exists today. The ophthalmology market continues to grow rapidly with annual sales in the US alone approaching $12 billion dollars. One product, for example Eyelea, marketed by Regeneron for wet AMD, exceeded $1.7 billion in sales in 2014 in only its third year on the market. This highlights the extent of the AMD disorder, which is rapidly becoming an epidemic in this and other developed countries. It's critical for us to be able to offer our therapy to as many patients as possible in the shortest time possible, and we're getting ready to begin our Phase II program in dry AMD, and our pivotal trial program for Stargardt's following a recent productive meeting with the European Medicines Agency, or EMA. Our number one corporate objective for 2015 is the initiation of the next phase of our clinical trials.
7/22/15 Shareholders Meeting
Paul Wotton: And I'm pleased to say that all of the market research we have conducted, and this is third party resources, it's not our own, shows that the market opportunity for what we're doing really stands up.
|
|
|
|
Post by nateb on Nov 21, 2015 19:00:19 GMT
The way I understand it you don't necessarily have to join anything. If they win and you were a shareholder in the time in question, then you will get a portion of the proceeds.
|
|
|
|
Post by actcforme on Nov 21, 2015 19:01:08 GMT
Jason and StemD DO NOT have a fiduciary responsibility to me, but Ocata Therapeutics DOES.
|
|
|
|
Post by sgottenyc on Nov 22, 2015 0:12:54 GMT
Good posts Patti!
One could add the discussion that occurred during the shareholder meeting 2 years ago concerning the pricing of the Staargadt's treatment' in the "6 figure" range. Unfortunately there's no transcript of that but I'm sure anyone who was there can attest to it.
|
|
|
|
Post by actcforme on Nov 22, 2015 3:21:38 GMT
Good posts Patti! One could add the discussion that occurred during the shareholder meeting 2 years ago concerning the pricing of the Staargadt's treatment' in the "6 figure" range. Unfortunately there's no transcript of that but I'm sure anyone who was there can attest to it. Q: What would one charge there, under private physician network? This is a relevant issue, you raised it during your presentation.
A: (Paul) We’re going through the pricing studies right now. What I can tell you is you only have to look at the other orphan drugs out there to sort of the level we’re thinking of charging for this product eventually so it’s probably going to be a six figure therapy. Beyond that, it’s still something we’re working on, but outside this room we have to communicate this to everybody if we start….It’s a very important designation to get because it enables you to charge the right price for the therapy, one which you should be rewarded for.
In red above, so do you think that Astellas read in their "electronic database" they were given full, unfettered access to, they saw about Ocata's plans to charge SIX FIGURES for the treatment. Well duh, Of course they did, and promptly decided to buy ALL of Ocata instead of just license the cells.
This whole deal stinks to high heaven.... that Astellas gets to know a helluva lot more about Ocata than those of us who own it!?!?!? I'd give my right arm to explain that in a court of law.
|
|
|
|
Post by actcforme on Nov 22, 2015 3:22:01 GMT
Paul before Q&A, SH meeting 2014 PLEASE NOTE THE COMMENT BY EDDY ON MA09 cell lines use:
Unique opportunity to take this therapy all the way in Stargardt’s and AMD to get it to market, to the people who need it. Where I am today with this company, this is a dream come to true to be able to take a unique therapy like this and turn it into a therapeutic.
About to initiate Phase II. Eddy has done well getting us ready to get into Phase II earlier than anticipated.
Icing on cake improvement in vision of safety trial.
Leading intellectual 23 issued patents, 70 or 80 pending, just covering the RPE program, let alone other programs like platelets, etc.
Quick word on those, those programs still within the company, seeking to monetize those programs at some point in the future, and why we brought Leroux join us as head of business development. Exciting time to be at ACTC, Ocata Therapeutics, web site goes live later this week. The company is regenerating itself with the technology available to us today.
Thanks for your attention and support.
Q&A:
Q: Can you comment on dog trials at Tufts Dr. Lanza?
Dr. Lanza: Obviously not ocular programs, some data in, not sure how much I can say.
Paul: (cut him off) Yeah, you can’t say much. You can say what’s publicly disclosed and we’ve actually just seen some data out of Tufts and can say it’s positive.
Q: 2a patients, are they finished, anything on data?
A: (Eddy) Safety is good. In terms of change in vision, difficult to say, some patients had cataract, known complication of vitrectomy surgery. It may take longer. We are following these patients upwards of 15 years.
Q: MAO9 lines not xeno free matter with agencies, can commercialize.
A: MA09 not xeno free but not prohibiting us, long as we’re meeting safety margins and seeing results we can move forward. Data trumps everything. Safety data we have gives us a lot of confidence.
Q: Slow down due to funding or protocol change, why, hard to find patients. Should be 44 patients, done 38. Is it hard to find 2a patients or funding?
A: More the former, safety study, patient seeing better has to be convinced it’s worthwhile to take the leap. Meet all eligibility criteria, Phase II will be more complicated. Some effort to squeeze patients through tube, not lack of effort and certainly have funding for trial. Why do Phase I when I can move to Phase II looking for proof of concept.
Q: Capital raise, expect it to happen concurrently with listing, what is reception of investment community towards your efforts.
A: (Ted) I’ll be very careful here talking about non-public information. Reception very favorable. Sort of, when we do a capital raise, and I won’t comment on those specifics, the uplist, go hand in hand. Couple of ways to qualify for Nasdaq, one 90 days, January 7th, second arm, book value on balance sheet of $5 million. Just under a million on Monday. Capital coming into company will get us there. Nasdaq will look at it at $5.1 million. An institutional capital raise good for lot of reasons. Nasdaq good for everybody in the room and why we are doing it.
(Paul) As result of Lancet, lot of interest in company from institutions, physicians, patients leaving their name and number to get back to them about the trial. ACTC has had very low profile until now. Everyone in this room believes in the science, but suddenly lot of people we still need to market the company to. The Lancet publication great publication for us. Pretty much every national newspaper and two days after publication announced, my phone didn’t stop ringing. Bob Lanza was dealing with journalists nonstop for 48 hours and did a great job. I’m delighted with reception we got. Renaming the company reason to get out there to show this is a very active company.
Q: Keep talking about institutional raises, associative uplisting. Phase II partnering off table.
A: (Paul) We have had pharmaceutical companies assess. Leroux coming here helping to make sure we do the right partnering transactions. Return on investment typically best end of Phase II. If someone offers us a huge check, access to our program and the right conditions, will look at it very, very carefully. The interest we’ve received in the program, eventually a partnering decision will be made.
Q: Expanding vet market. We’ve used stem cells on horses for 10 years. Why wouldn’t you consider doing some form of divesture of the veterinary division.
A: (Paul) Very good question and same question should apply to platelets, an area under consideration.
Q: NED lines, will there be a bridge of cell lines.
A: (Paul) We have a lot of alternative cell lines at the company. Without giving specific answer to question because of the nature of confidentiality here. I would say the manufacturing team is completely on top of this, as is the development team in terms of working with the agency and both here FDA and the other control agencies are extremely supportive here, very helpful.
Q: Comment made on one of the therapies being designated as a therapy and being able to be paid in the UK. Can you comment on that?
A: (Paul) Yes there is an Advanced Technology designation in Europe which is necessary for biotechnology companies like us, to be able to get our therapy registered then you can price it.
Q: At what point do you expect that to happen?
A: (Paul) Imminently.
Q: Really?
A: (Paul) Yes.
Q: What would one charge there, under private physician network? This is a relevant issue, you raised it during your presentation.
A: (Paul) We’re going through the pricing studies right now. What I can tell you is you only have to look at the other orphan drugs out there to sort of the level we’re thinking of charging for this product eventually so it’s probably going to be a six figure therapy. Beyond that, it’s still something we’re working on, but outside this room we have to communicate this to everybody if we start….It’s a very important designation to get because it enables you to charge the right price for the therapy, one which you should be rewarded for.
Q: Only in the UK?
A: (Paul) No it’s the European designation.
Q: The shares recently issued, are you planning on selling them to fund Phase II/III or is the company fully funded to go through the next phases without those shares?
A: (Ted) Are you referring to shares just authorized? (Yes). Those are authorized, they’re not issued. That’s there for us to ultimately issue to fund the company should be for the next several years and yes as you saw from the presentations, obviously the key thrust is to fund the clinical trials, building the company around this therapeutic pipeline, the lead indication being the RPE as we really expand the clinical capability of the company with the investigator sites during 2015 as we ramp up these trials and in early 2016 we’ll know what we have and to us that’s the biggest catalyst and creator of shareholder value.
Q: Can you comment on blood studies, platelets?
A: (Paul) We’re just in the process of starting discussions with a couple of companies on platelet work.
|
|
